Stock Price Quote

SHILPA MEDICARE LTD.

NSE : SHILPAMEDBSE : 530549ISIN CODE : INE790G01031Industry : Pharmaceuticals & DrugsHouse : Private
BSE430.95-0.9 (-0.21 %)
PREV CLOSE ( ) 431.85
OPEN PRICE ( ) 437.85
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 22516
TODAY'S LOW / HIGH ( )427.55 440.00
52 WK LOW / HIGH ( )222.4 455
NSE430.60-1.5 (-0.35 %)
PREV CLOSE( ) 432.10
OPEN PRICE ( ) 433.85
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 430.60 (2565)
VOLUME 438221
TODAY'S LOW / HIGH( ) 427.00 440.90
52 WK LOW / HIGH ( )222.6 454.8
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1987
Management Info
Omprakash Inani - Chairman Vishnukant Bhutada - Managing Director
Registered Office

Address Shilpa House,#12-6-214/ A1,Hyderabad Road,
Raichur,
Karnataka-584135

Phone 08532-238704

Email info@vbshilpa.com

Website www.vbshilpa.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX

NEWS

26Feb Shilpa Medicare informs about disclosu
Shilpa Medicare has informed that the company, headquartered at Raichur,..
07Feb EMA concludes inspection at Shilpa Med
European Medicines Agency (EMA) has concluded inspection at Shilpa Medic..
06Feb Rights Announcement
Rights Issue & Quarterly Results & Preferential Issue of shares
27Jan Shilpa Medicare informs about disclosu
Shilpa Medicare has informed that the company, Unit 4, Jadcherla, Telang..
19Jan Shilpa Medicare informs about disclosure
Shilpa Medicare has informed that Shilpa Medicare, headquartered at Raic..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit26.98571.94
Gross Profit 39.09 -582.75
Operating Profit 190.29246.44
Net Sales 639.792477.02

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  28639.35 (0.55%)
M.Cap ( in Cr)60856.62
Bharat Parenterals (BSE)
peergroup  1147.65 (10.28%)
M.Cap ( in Cr)667.89
Astrazeneca Pharma I (BSE)
peergroup  5567.65 (1.95%)
M.Cap ( in Cr)13919.13
Neuland Laboratories (BSE)
peergroup  7063.75 (1.37%)
M.Cap ( in Cr)9062.71
Mankind Pharma (BSE)
peergroup  2097.55 (1.58%)
M.Cap ( in Cr)84025.43

Shareholding Pattern

PROMOTERS 50.01%
NON-INSTITUTION 41.41%
MUTUAL FUNDS/UTI 0.06%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Shilpa Medicare Ltd.

Shilpa Medicare Ltd. was incorporated in the year 1987. Its today's share price is 430.95. Its current market capitalisation stands at Rs 3740.73 Cr. In the latest quarter, company has reported Gross Sales of Rs. 2477.02 Cr and Total Income of Rs.3275.19 Cr. The company's management includes Ritu Tiwary, Sharath Reddy Kalakota, Anita Bandyopadhyay, Kamal K Sharma, Arvind Vasudeva, Hetal Madhukant Gandhi, Vishnukant Bhutada, Omprakash Inani.

It is listed on the BSE with a BSE Code of 530549 , NSE with an NSE Symbol of SHILPAMED and ISIN of INE790G01031. It's Registered office is at Shilpa House,#12-6-214/ A1,Hyderabad RoadRaichur-584135, Karnataka. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Bohara Bhandari Bung & Associates, Bohara Bhandari Bung & Associates LLP, Brahmayya & Co

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.